Across TCGA pan-cancer cohorts, ARL16 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ARL16 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ARL16 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ARL16 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LSCC and CCRCC are the cancer types where ARL16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	0.878	0.381	.027	3	view →
CCRCC	DFS	Median	All	0.954	0.301	.018	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: ARL16 tumor-vs-normal RNA expression · all ARL16 data types